FDA Approves QIAGEN N.V. KRAS Test for Use With Eli Lilly and Company and Bristol-Myers Squibb Company’s Cancer Drug Erbitux

QIAGEN NV has received US FDA approval to market the therascreen KRAS RGQ PCR Kit (therascreen KRAS test) to provide guidance on the use of Erbitux (cetuximab) as a treatment in patients with metastat…
Read the full story: BioSpace.com Featured News